Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Raptiva · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Raptiva | DRUG | - |
Inclusion Criteria: * Signed informed consent * Plaque psoriasis covering ³10% of total BSA (see Appendix A) * Diagnosis of psoriasis for at least 6 months * A minimum PASI score of 12.0 at screening (see Appendix A) * Patients who are either not controlled by, intolerant to or contraindicated to a...
Raptiva is used for the treatment of moderate to severe psoriasis. It is an investigational small molecule being developed for this dermatological condition. The drug has been studied in a Phase 3 clinical trial, though it remains in clinical development and is not yet approved.
Raptiva is being developed by Merck KGaA, a company traded under the ticker MKGAF. The drug is currently in Phase 3 clinical development for moderate to severe psoriasis. Merck KGaA is conducting research to evaluate the safety and efficacy of this investigational therapy.
Raptiva is in Phase 3 clinical development. It has completed one Phase 3 trial, the CLEAR Study, which enrolled 793 participants with moderate to severe psoriasis. The drug is still investigational and has not been approved for commercial use.
Raptiva has been studied in the CLEAR Study, a Phase 3 clinical trial with the identifier NCT00256139. This completed trial enrolled 793 participants with moderate to severe psoriasis in Switzerland. The study was randomized and double-blind, though it did not use a control group.
Raptiva is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for moderate to severe psoriasis. The drug has completed a Phase 3 trial, but it remains under investigation and has not received regulatory approval.